Showing results (71-80 of 84) with videos related to
Sort By:
Pageof 9
Journal of Sports Sciences|February 21, 2025
Relationship between the cervical spine and impacts whilst heading the ball in adolescent male soccer playersFelix T Leung, Hugo G Espinosa, David Rowlands, et al.Diabetes, Obesity & Metabolism|June 9, 2026
Pre-Exercise Galactose or Lactose Reduces Glycaemic Excursions During Exercise in Adults With Type 1 Diabetes: A Randomised, Double-Blind, Crossover TrialKaroline R Schmidt, Rakel F Johansen, Simon B Riis, et al.Food Microbiology|February 21, 2026
Prevalence of foodborne pathogens and indicator microorganisms on Arizona and California grown commercial cantaloupe melons and in environmental samplesRichard Park, David Rowlands, Libin Zhu, et al.Journal of Clinical Monitoring and Computing|September 13, 2025
Post-operative cerebral oximetry for detection of low-cardiac output syndrome after coronary artery bypass surgeryMiriam Silaschi, Jacqueline Kruse, Maria Wittmann, et al.Molecular Pharmaceutics|May 24, 2022
iBCS: 2. Mechanistic Modeling of Pulmonary Availability of Inhaled Drugs versus Critical Product AttributesPer Bäckman, Antonio Cabal, Andy Clark, et al.Molecular Pharmaceutics|May 16, 2022
iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification SystemJayne E Hastedt, Per Bäckman, Antonio Cabal, et al.Cancer Research|May 3, 2003
Reactivity with A monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genomePaul G Murray, David Lissauer, Jia Junying, et al.Molecular Pharmaceutics|December 7, 2023
iBCS: 3. A Biopharmaceutics Classification System for Orally Inhaled Drug ProductsJayne E Hastedt, Per Bäckman, Antonio Cabal, et al.Molecular Pharmaceutics|March 13, 2025
iBCS: 4. Application of the Inhalation Biopharmaceutics Classification System to the Development of Orally Inhaled Drug ProductsBen Forbes, Per Bäckman, Antonio Cabal, et al.Journal of Medicinal Chemistry|June 9, 2023
Design and Synthesis of Inhibitors of the E3 Ligase SMAD Specific E3 Ubiquitin Protein Ligase 1 as a Treatment for Lung Remodeling in Pulmonary Arterial HypertensionDuncan E Shaw, Nichola Smith, Rene Beerli, et al.Pageof 9